Researchers worldwide can access orthotopic patient-derived xenograft models to speed discovery and test novel therapies for childhood brain tumors.Read more
Among people who have the most common type of lung cancer, up to 40% develop metastatic brain tumors, with an average survival time of less than six months.Read more
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.Read more
MTX110 is a new formulation of panobinostat, a chemotherapy drug that has shown promise in laboratory models of medulloblastoma, the most common malignant brain tumor in children. Now, MTX110 is the focus of a novel trial that places the therapy directly into the fourth ventricle of the brain to treat patients with recurrent medulloblastoma.Read more
An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.Read more
Collaboration co-led by researchers at St. Jude Children’s Research Hospital discovers a novel predisposition gene in pediatric medulloblastoma.Read more
Chemotherapy has been so unsuccessful against DIPG that researchers have questioned whether chemotherapy drugs are even able to reach the cancer. University of Colorado Cancer Center study shows, “… medicine does reach DIPG tissue in good quantities that have the potential to be effective against the tumor,” says lead researcher.
Nationally-known developer Chris Jeffries and his wife Lisa have donated $25 million to Henry Ford Health System, the largest single gift from an individual in the health system’s 105-year history. This historic gift will rapidly accelerate the growth and expansion of Henry Ford’s Precision Medicine program, with the ultimate goal of creating a Precision Health Center. The efforts will have a robust focus on the advancement of cancer research and treatment, while also expanding to other medical specialties treating behavioral health, cardiovascular and metabolic diseases.Read more
When you’re facing a cancer diagnosis with an average survival span of 12 to 18 months, every milestone is a victory. That makes each wedding invitation, graduation announcement and birthday photo that UCI neuro-oncologist Dr. Daniela Bota receives from her patients a cherished validation of her 12 years of groundbreaking research on glioblastoma multiforme, the most aggressive form of brain cancer.Read more
University of California San Diego School of Medicine researchers created a new type of brain cancer model for glioblastoma using stem cells, CRISPR and gene sequencing.Read more
Promising intracellular protein-based therapeutics have been of limited use due to the difficulty of delivery into diseased cells. Now bioengineers have developed nanoparticles that can deliver these therapeutics to their targets—avoiding degradation and toxic interactions with healthy tissues.Read more
University Hospitals Seidman Cancer Center treated its first patient in a new clinical trial to validate the groundbreaking effects of the poliovirus on glioblastoma (GBM), a deadly Grade IV cancer of the brain.
UH is the only Midwest site participating in this clinical trial, which was initiated at Duke Cancer Institute in Durham, NC. The original study, which ran from 2012-2017, was published in New England Journal of Medicine in July 2018 as well as highlighted on “60 Minutes” in 2015 and again in 2018. The study found that survival rates were significantly higher in glioblastoma patients who received an intratumoral infusion of a modified viral chimera combining the polio and rhinoviruses (PVSRIPO immunotherapy) compared to patients receiving standard treatment at the same institution.Read more